Fig. 1: In vitro screening of LNA ASOs targeting SARS-CoV-2.
a Schematic representation of the genome structure and the regions targeted by LNA ASOs. b, c The SARS-CoV-2 WA1 strain-infected Huh-7 cells treated with LNA ASO (100 nM) and cell culture medium were collected at 48 hpi. Viral RNA levels were analyzed by RT-qPCR for LNA ASO screening. Each LNA ASO was tested in duplicate and compared with in vitro Mixmer control LNA ASO or Gapmer control LNA ASO. d Dose-dependent effects of 5’-ASO#26 were evaluated in infected Huh-7 cells with increasing doses (N = 3) of the LNA ASO (as indicated) by RT-qPCR. The exact p-values stated in the following order: Nucleocapsid group and then Spike group ((Mixmer Ctrl vs. 5’_ASO#26), at 5 nM: P = 0.8279, **** P < 0.0001; at 10 nM: **P = 0.0012, *** P = 0.0002; at 20 nM: ***P = 0.0007, ****P < 0.0001; at 50 nM: *** P = 0.0002, **** P < 0.0001; at 100 nM: **** P < 0.0001, **** P < 0.0001. e The infectious virus was measured by TCID50 assay. The infected Huh-7 cells with different doses (N = 3) of LNA ASO treatment were collected at 48 hpi. The exact p-values stated here: at 5 nM, *** P = 0.0002; at 10 nM, *** P = 0.0003; at 20 nM, **** P < 0.0001; at 50 nM, **** P < 0.0001; at 100 nM, **** P < 0.0001. For d and e, one-way ANOVA with Dunnett’s test was used to determine significance (** P < 0.01, *** P < 0.001, **** P < 0.0001, P > 0.05, ns, not significant). Source data are provided as a Source Data file.
